Evolutionary artificial intelligence based peptide discoveries for effective Covid-19 therapeutics
- PMID: 32980462
- PMCID: PMC7832815
- DOI: 10.1016/j.bbadis.2020.165978
Evolutionary artificial intelligence based peptide discoveries for effective Covid-19 therapeutics
Abstract
An epidemic caused by COVID-19 in China turned into pandemic within a short duration affecting countries worldwide. Researchers and companies around the world are working on all the possible strategies to develop a curative or preventive strategy for the same, which includes vaccine development, drug repurposing, plasma therapy, and drug discovery based on Artificial intelligence. Therapeutic approaches based on Computational biology and Machine-learning algorithms are specially considered, with a view that these could provide a fast and accurate outcome in the present scenario. As an effort towards developing possible therapeutics for COVID-19, we have used machine-learning algorithms for the generation of alignment kernels from diverse viral sequences of Covid-19 reported from India, China, Italy and USA. Using these diverse sequences we have identified the conserved motifs and subsequently a peptide library was designed against them. Of these, 4 peptides have shown strong binding affinity against the main protease of SARS-CoV-2 (Mpro) and also maintained their stability and specificity under physiological conditions as observed through MD Simulations. Our data suggest that these evolutionary peptides against COVID-19 if found effective may provide cross-protection against diverse Covid-19 variants.
Keywords: Artificial intelligence; Computational biology; Covid-19; Evolutionary peptides; SARS-CoV-2.
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures







Similar articles
-
Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation.Int J Mol Sci. 2021 Aug 30;22(17):9427. doi: 10.3390/ijms22179427. Int J Mol Sci. 2021. PMID: 34502335 Free PMC article.
-
Fighting COVID-19 with Artificial Intelligence.Methods Mol Biol. 2022;2390:103-112. doi: 10.1007/978-1-0716-1787-8_3. Methods Mol Biol. 2022. PMID: 34731465
-
Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.Chem Biol Drug Des. 2021 Apr;97(4):836-853. doi: 10.1111/cbdd.13812. Epub 2020 Dec 22. Chem Biol Drug Des. 2021. PMID: 33289334
-
Artificial Intelligence Technologies for COVID-19 De Novo Drug Design.Int J Mol Sci. 2022 Mar 17;23(6):3261. doi: 10.3390/ijms23063261. Int J Mol Sci. 2022. PMID: 35328682 Free PMC article. Review.
-
Emerging role of artificial intelligence in therapeutics for COVID-19: a systematic review.J Biomol Struct Dyn. 2022 Jul;40(10):4750-4765. doi: 10.1080/07391102.2020.1855250. Epub 2020 Dec 10. J Biomol Struct Dyn. 2022. PMID: 33300456 Free PMC article.
Cited by
-
Role of artificial intelligence in peptide vaccine design against RNA viruses.Inform Med Unlocked. 2021;26:100768. doi: 10.1016/j.imu.2021.100768. Epub 2021 Oct 23. Inform Med Unlocked. 2021. PMID: 34722851 Free PMC article. Review.
-
Development of superior antibodies against the S-protein of SARS-Cov-2 using macrocyclic epitopes.Arab J Chem. 2022 Mar;15(3):103631. doi: 10.1016/j.arabjc.2021.103631. Epub 2021 Dec 10. Arab J Chem. 2022. PMID: 34909055 Free PMC article.
-
How Artificial Intelligence and New Technologies Can Help the Management of the COVID-19 Pandemic.Int J Environ Res Public Health. 2021 Jul 19;18(14):7648. doi: 10.3390/ijerph18147648. Int J Environ Res Public Health. 2021. PMID: 34300099 Free PMC article. Review.
-
The Artificial Intelligence-Powered New Era in Pharmaceutical Research and Development: A Review.AAPS PharmSciTech. 2024 Aug 15;25(6):188. doi: 10.1208/s12249-024-02901-y. AAPS PharmSciTech. 2024. PMID: 39147952 Review.
-
Therapeutic peptides: current applications and future directions.Signal Transduct Target Ther. 2022 Feb 14;7(1):48. doi: 10.1038/s41392-022-00904-4. Signal Transduct Target Ther. 2022. PMID: 35165272 Free PMC article. Review.
References
-
- Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed
-
- Dhama K., Sharun K., Tiwari R., Dadar M., Malik Y.S., Singh K.P., Chaicumpa W. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum. Vaccines Immunother. 2020;16:1232–1238. doi: 10.1080/21645515.2020.1735227. - DOI - PMC - PubMed
-
- Wang Manli, Cao Ruiyuan, Zhang Leike, Yang Xinglou, Liu Jia, Xu Mingyue, Shi Zhengli, Hu Zhihong, Wu Zhong, Xiao Gengfu. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. https://www.nature.com/articles/s41422-020-0282-0 - PMC - PubMed
-
- Naqvi A.A.T., Fatima K., Mohammad T., Fatima U., Singh I.K., Singh A., Atif S.M., Hariprasad G., Hasan G.M., Hassan M.I. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. Biochim. Biophys. Acta Mol. basis Dis. 1866;2020 doi: 10.1016/j.bbadis.2020.165878. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous